Information Library

High-quality studies - Europe

To learn more about a particular aspect of Quintiles’ pharma services, biotech development or drug commercialization services, select a topic at left. If you’ve already specified a choice, you may narrow your search by selecting additional categories in any order. For example, for information on oncology drug development, start by selecting oncology. Then you can narrow your search to Central Lab, News Releases and Europe.

See all

  • Sort by:
  • Most Recent
  • Title

  • Malaysia Prime Site

    July 2, 2010
    Adam Chasse, Sr. Director, Access to Patients explains the importance of Prime Sites and the impact of our clinical research partnership with the University of Malaya Medical Centre in Malaysia.

  • Rigorous Planning

    May 9, 2010
    A large pharma company needed to establish a pilot screening program with 50 participating practices, identify 4,500 people at risk and perform 2,500 bone densitometries in just nine months.

  • NHS Motivating Patients

    May 7, 2010
    In 2008, the NHS announced plans to offer free health checks for heart disease, stroke, diabetes and kidney disease. Learn why Quintiles was the right ally for the NHS to successfully launch this cardio risk assessment program.

  • Clinical – smarter trials, accelerated outcomes

    April 2, 2010
    Quintiles will work with you to plan and execute the smartest clinical trials and post-marketing studies, informed by a holistic view of strategic, operational, regulatory and marketplace issues.

  • QUINTILES EXTENDS PHASE I CAPACITY AND CAPABILITIES

    March 8, 2010 – Quintiles announced the opening of its expanded research facility in London, UK, increasing its Phase I capacity and extending its ability to drive progress in translational medicine.

  • The Value of Reviewing Existing EU Risk Management Plans

    February 12, 2010
    Drug Safety experts Cheryl Key, Barry Mulchrone and Karen Wai describe an electronic database for tracking RMPs for drugs approved in the European Union and explain why it is crucial for sponsors submitting marketing applications to have a thorough knowledge of safety plans already required for similar products.

  • Enrollment Target Acheived Early for Ulcerative Colitis Study

    January 19, 2010
    Although faced with the challenge of recruiting for this small patient population, enrollment was completed two months ahead of schedule.

  • New FDA Guidance on Antidiabetic Therapies

    December 11, 2009
    Understanding the FDA Guidance on Assessing Cardiovascular Risks for new Antidiabetic Therapies. Learn what FDA cardiac safety requirements may mean for your development program.

  • QUINTILES PARTNERS WITH FOUNDATION TRUST & UNIVERSITY TO IMPROVE PATIENT CARE AND DRIVE EFFICIENCY IN CLINICAL RESEARCH

    October 26, 2009 - A significant step in driving innovation, improving patient care and increasing efficiency in early stage clinical research was taken today with the announcement that two of the UK’s leading institutions - Guy’s and St Thomas’ NHS Foundation Trust and King’s College London - have signed a collaborative agreement with Quintiles, the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide.

  • Validated Biomarker Menu

    July 14, 2009
    A comprehensive menu of validated cell, fluid and tissue based biomarker assays.

Page 1 of 1 (10 results)

Subscribe to Email Based on Your Interests

Set preferences